Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: A pilot study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 5, 2008, Pages 1185-1190

  Okamoto, Tatsuya ^a   Yoshimura, Reiji ^a   Ikenouchi Sugita, Atsuko ^a   Hori, Hikaru ^a   Umene Nakano, Wakako ^a   Inoue, Yoshiaki ^a   Ueda, Nobuhisa ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

3 methoxy 4 hydroxyphenylglycol; Brain derived neurotrophic factor; Electroconvulsive therapy; Homovanillic acid; Nitric oxide; Refractory depression

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATROPINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOMIPRAMINE; HOMOVANILLIC ACID; IMIPRAMINE; MILNACIPRAN; MONOCLONAL ANTIBODY; NITRIC OXIDE; PAROXETINE; PROPOFOL; SERTRALINE; SULPIRIDE; SUXAMETHONIUM; VECURONIUM;

ADULT; AGED; ARTICLE; BIPOLAR I DISORDER; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; DEPRESSION; DOPAMINERGIC NERVE CELL; ELECTROCHEMICAL DETECTION; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAM; ELECTROMYOGRAM; FEMALE; HAMILTON SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; MAJOR DEPRESSION; MALE; MEDICAL INSTRUMENTATION; MENTAL DISEASE; PATIENT MONITORING; PILOT STUDY; PSYCHOPHARMACOTHERAPY; TREATMENT OUTCOME;

ADULT; AGED; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER; ELECTROCONVULSIVE THERAPY; FEMALE; HOMOVANILLIC ACID; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; STATISTICS, NONPARAMETRIC;

EID: 49849103484     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.02.009     Document Type: Article

References (54)

1. Aberg-Wistedt A., Martensson B., Bertilsson L., and Malmgren R. Electroconvulsive therapy effects on cerebrospinal fluid monoamine metabolites and platelet serotonin uptake in melancholia. Convuls Ther 2 (1986) 91-98
2. Abrams R., Essman W.B., Taylor M.A., and Fink M. Concentration of 5-hydroxyindoleacetic acid, homovanillic acid, and tryptophan in the cerebrospinal fluid of depressed patients before and after ECT. Biol Psychiatry 11 (1976) 85-90
3. Abrams R., Swartz C., and Vedak C. Antidepressant effects of right versus left unilateral ECT and the lateralization theory of ECT action. Am J Psychiatry 146 (1989) 1190-1192
4. Altar C.A., Laeng P., Jurata L.W., Brockman J.A., Lemire A., Bullard J., et al. Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci 21 (2004) 2667-2677
5. Alter C.A., Boylan C.B., Lackson C., Hershenton S., Miller J., Wiegand S.J., et al. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc Natl Acad Sci U S A 89 (1992) 11347-11351
6. Aydemir C., Deveci A., and Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 261-265
7. Bocchio-Chiavetto L., Zanardi R., Bortolomasi M., Abate M., Segala M., Giacopuzzi M., et al. Electroconvulsive therapy (ECT) increases serum brain-derived neurotrophic factor (BDNF) in drug registant depressed patients. Eur Neuropsychopharmacol 16 (2006) 620-624
8. Burt T., Lisanby S.H., and Sackeim H.A. Neuropsychiatric applications of transcranial magnetic stimulation: analysis. Int J Neuropsychopharmacol 5 (2002) 73-103
9. Chrapko W.E., Jurasz P., Radomski M.W., Lara N., Archer S.L., and Le Melledo J.M. Decreased platelet nitric oxide synthesa activity and plasma nitric oxide metabolisms in major depressive disorder. Biol Psychiatry 56 (2004) 129-134
10. Chrapko W.E., Jurasz P., Radmski M.W., Archer S.L., Newman S.C., Baker G., et al. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology 31 (2006) 1286-1293
11. Devanand D.P., Bowers Jr. M.B., Hoffman Jr. F.J., and Sackeim H.A. Acute and subacute effects of ECT on plasma HVA, MHPG, and prolactin. Biol Psychiatry 26 (1989) 408-412
12. Do T., Kerr B., and Kuzhikandathil E.V. Brain-derived neurotrophic factor regulates the expression of D1 dopamine receptors. J Neurochem 100 (2007) 416-428
13. Durman R.S., Heninger G.R., and Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 54 (1997) 597-605
14. Duman R.S., Malberg J., Nakagawa S., and D' Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 48 (2000) 732-739
15. Dwivedi Y., Rdzavi H.S., Conley R.R., Roberts R.C., Tamminga C.A., and Pondey G.N. Altered gene expression of brain-derived neurotrophic factor receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 60 (2003) 804-815
16. Figurov A., Pozzo-Miller L.D., Olafsson P., Wang T., and Lu B. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 381 (2006) 706-709
17. Fiddler R.M. Collaborative study of modified AOAC method of analysis for nitrite in meat and meat products. J Assoc Off Anal Chem 60 (1977) 594
18. Gonul A.S., Akdeniz F., Taneli F., Donat O., Eker C., and Vahip S. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 255 (2005) 381-386
19. Goto M., Yoshimura R., Kakihara S., Shinkai K., Yamada Y., Kaji K., et al. Risperidone in the treatment of psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 701-707
20. Gronli O, Stensland GO, Wynn R, Olstad R. Neurotrophic factors in serum following ECT: a pilot study. World J Biol Psychiatry 2007;21:1-7.
21. Harnryd C., Bjerkenstedt L., Grimm V.E., and Sedvall G. Reduction of MOPEG levels in cerebrospinal fluid of psychiatric women after electroconvulsive treatment. Psychopharmacology 64 (1979) 131-134
22. Harker L.A., Roskos L.K., Marzec U.M., Carter R.A., Cherry J.K., Sundell B., et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 95 (2000) 2514-2522
23. Hussain F., and Cochrane R. Depression in South Asian women living in the UK: a review of the literature with implications for service provision. Transcult Psychiatry 41 (2004) 253-270
24. Jori A., Dolfini E., Casati C., and Argenta G. Effect of ECT and imipramine treatment on the concentration of 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) in the cerebrospinal fluid of depressed patients. Psychopharmacologia 44 (1975) 87-90
25. Juric D.M., Miklics S., and Carman-Krzan M. Monoaminergic neuronal activity up-regulates BDNF synthesis in cultured neonatal rat astrocytes. Brain Res 1108 (2006) 54-62
26. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., and Aubry J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 109 (2000) 143-148
27. Karege F., Schward M., and Cisse M. Postnatal development profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 328 (2000) 261-264
28. Lang U.E., Hellweg R., Seifert F., Schubert F., and Gallinat J. Correlation between serum brain-derived neurotrophic factor level and in vivo marker of cortical integrity. Biol Psychiatry 62 (2007) 530-535
29. Lerer B., and Belmarker R.H. Receptors and the mechanism of action of ECT. Biol Psychiatry 17 (1982) 497-511
30. Linnoila M., Karoum F., Rosenthal N., and Potter W.Z. Electroconvulsive treatment and lithium carbonate. Their effects on norepinephrine metabolism in patients with primary major depressions. Arch Gen Psychiatry 40 (1983) 677-680
31. Linnoila M., Litovitz G., Scheinin M., Chang M.D., and Culler N.R. Effects of electroconvulsive treatment on monoamine metabolites, growth hormone, and prolactin in plasma. Biol Psychiatry 19 (1984) 79-84
32. Lommatzsch M., Zingler D., Schuhbaeck K., Schuhbaeck K., Schloetcke K., Zingler C., et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 26 (2005) 115-123
33. Lykouras L., Markianos M., Hatzimanolis J., Malliaras D., and Stefanis C. Biogenic amine metabolites during electroconvulsive therapy of melancholic patients. Convuls Ther 6 (1990) 266-272
34. Marano C.M., Phatak P., Vemulapalli U.R., Sasan A., Nalbandyan M.R., Ramanujam S., et al. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. J Clin Psychiatry 68 (2007) 512-517
35. Minegishi A., and Ishizaki T. Determination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric determination. J Chromatogr 311 (1984) 51-57
36. Mitoma, M., Yoshimura, R., Sugita, A., Umene, W., Hori, H., Nakano, H., et al. Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress? Prog Neuropsychopharmacol Biol Psychiatry 2008;32:679-85.
37. Navarro V., Gasto C., Lomena F., Mateos J.J., Portella M.J., Massana G., et al. Frontal cerebral perfusion after antidepressant drug treatment versus ECT in elderly patients with major depression: a 12-month follow-up control study. J Clin Psychiatry 65 (2004) 656-661
38. Nibuya M., Morinobu S., and Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant treatments. J Neurosci 15 (1995) 7539-7547
39. Noh J.S., Kim E.Y., Kang J.S., Kim H.R., Oh Y.J., and Gwag B.J. Neurotoxic and neuroprotective actions of catecholamines in cortical neurons. Exp Neurol 159 (1999) 217-224
40. Pan W., Banks W.A., Fasold M.B., Blush J., and Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37 (1998) 1553-1561
41. Paredes D., Granholm A.C., and Bickford P.C. Effects of NGF and BDNF on baseline glutamate and dopamine release in the hippocampal formation of the adult rat. Brain Res 1141 (2007) 56-64
42. Podusto J.F., and Curran G.L. Permeability at the blood-brain and blood nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Mol Brain Res 36 (1996) 280-286
43. Rosen Y., Reznik I., Sluvis A., Kaplan D., and Mester R. The significance of the nitric oxide in electro-convulsive therapy: a proposed neurophysiological mechanism. Med Hypotheses 60 (2003) 424-429
44. Shimizu E., Hashimoto K., Okuma N., Koike K., Komatsu N., Kumakiri C., et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54 (2003) 70-75
45. Shinkai K., Yoshimura R., Ueda N., Okamoto K., and Nakamura J. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol 24 (2004) 11-17
46. Shoval G., and Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 15 (2005) 319-329
47. Thase M.E., and Rush A.J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58 suppl 13 (1997) 23-29
48. Ueda N., Yoshimura R., Shinkai K., and Nakamura J. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry 35 (2002) 175-181
49. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorder: a systematic review and metaanalysis. Lancet 361 (2003) 799-808
50. Weissman M.M., Bland R.C., Canino G.J., Favalli C., Greenwald S., Hwu H.G., et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 276 (1996) 293-299
51. Yeung P.K., Buckley S.J., Pedder S.C., and Dingemanse J. Determination of 3,4-dihydroxyphenylacetic acid and 5-hydroxyindoleacetic acid in human plasma by a simple and rapid high-performance liquid chromatography assay. J Pharm Sci 85 (1996) 451-453
52. Yoshimura R., Nakamura J., Shinkai K., and Ueda N. Clinical response to antidepressants treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 611-616
53. Yoshimura R., Mitoma M., Sugita A., Hori H., Okamoto T., Umene W., et al. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 31 (2007) 1034-1037
54. Yukimasa T., Yoshimura R., Tamagawa A., Uozumi T., Shinkai K., Ueda N., et al. High-frequency repetitive transcranial magnetic srtimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors. Pharmacopsychiatry 39 (2006) 52-59